{"id":51348,"date":"2026-04-19T03:55:43","date_gmt":"2026-04-19T03:55:43","guid":{"rendered":"https:\/\/www.europesays.com\/ch\/51348\/"},"modified":"2026-04-19T03:55:43","modified_gmt":"2026-04-19T03:55:43","slug":"roches-dac-investment-big-pharmas-lavish-ceo-bumps-2","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/ch\/51348\/","title":{"rendered":"Roche\u2019s DAC investment; Big Pharma\u2019s lavish CEO bumps"},"content":{"rendered":"\n

This story was originally published on PharmaVoice<\/a>. To receive daily news and insights, subscribe to our free daily PharmaVoice newsletter<\/a>. <\/p>\n

Some of the biggest news and trends captured in PharmaVoice\u2019s newsletter this week. Sign up here<\/a>\u00a0to receive the newsletter daily.<\/p>\n

There\u2019s a cooler version of ADCs emerging in cancer R&D. Called DACs, or degrader-antibody conjugates, the new modality combines the power of targeted protein degraders with ADCs, and is increasingly driving deals by Big Pharmas.<\/p>\n

Roche laid down $20 million<\/a> last week to deepen a partnership with C4 Therapeutics that could eventually be worth up to $1 billion and is centered around DAC development. The company is joining several large pharmas \u2014 including Bristol Myers Squibb and Merck & Co. \u2014 investing in early-stage DAC research.<\/p>\n

But not all Big Pharma companies are jumping on the same R&D bandwagons, and instead, many have become more specialized. This week, we looked closer at how pharma giants are leaning into their unique R&D strengths<\/a>.<\/p>\n

In 1965, the average CEO of a major U.S. company brought home 21 times the compensation<\/a> of a standard employee at their firm, according to the Economic Policy Institute. By 2024, that ratio shot up to 281 times the typical worker\u2019s salary, with multiple peaks and valleys in between.<\/p>\n

Big Pharma has ridden that wave, lavishing its CEOs with multimillion-dollar packages that leave even its skilled employee base well behind. J&J\u2019s Joaquin Duato, Pfizer\u2019s Albert Bourla, Eli Lilly\u2019s David Ricks and Merck & Co.\u2019s Rob Davis were the top earners in 2024<\/a> compared to their employees, especially as their businesses thrived in the dawn of new obesity drugs and other sales juggernauts.<\/p>\n

This week, we explored what some Big Pharma CEOs pulled in through 2025<\/a> and the sizable pay raises they picked up along the way.<\/p>\n

Revolution Medicines took a victory lap this week with a clinical readout that could trigger a \u201ctransformative advance\u201d in pancreatic cancer, according to the company\u2019s CEO<\/a>. In a pivotal phase 3 trial, Revolution\u2019s RAS-targeting candidate daraxonrasib nearly doubled the survival rate to 13.2 months compared to 6.7 months with chemotherapy alone.<\/p>\n

Drug researchers at Actuate Therapeutics also reported a pancreatic cancer win this week. In a phase 2 trial, the one-year survival rate doubled<\/a> for patients taking the biotech\u2019s potential first-in-class pancreatic cancer treatment, which targets GSK-3\u03b2.<\/p>\n

While oncology researchers make headway in tough-to-treat indications, they\u2019re also in pursuit of challenging targets. This week, we looked at the industry\u2019s quest to drug p53<\/a> and how success could impact cancer R&D.<\/p>\n","protected":false},"excerpt":{"rendered":"This story was originally published on PharmaVoice. To receive daily news and insights, subscribe to our free daily…\n","protected":false},"author":2,"featured_media":51349,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[124],"tags":[8330,29267,24061,9073,29266,134],"class_list":{"0":"post-51348","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-roche","8":"tag-big-pharma","9":"tag-big-pharmas","10":"tag-bristol-myers-squibb","11":"tag-merck-co","12":"tag-pancreatic-cancer","13":"tag-roche"},"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@ch\/116429358547748280","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts\/51348","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/comments?post=51348"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts\/51348\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/media\/51349"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/media?parent=51348"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/categories?post=51348"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/tags?post=51348"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}